![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAP3K8 |
Gene summary for MAP3K8 |
![]() |
Gene information | Species | Human | Gene symbol | MAP3K8 | Gene ID | 1326 |
Gene name | mitogen-activated protein kinase kinase kinase 8 | |
Gene Alias | AURA2 | |
Cytomap | 10p11.23 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P41279 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1326 | MAP3K8 | AEH-subject1 | Human | Endometrium | AEH | 1.05e-31 | 7.37e-01 | -0.3059 |
1326 | MAP3K8 | AEH-subject2 | Human | Endometrium | AEH | 1.08e-13 | 4.60e-01 | -0.2525 |
1326 | MAP3K8 | AEH-subject3 | Human | Endometrium | AEH | 4.06e-07 | 3.55e-01 | -0.2576 |
1326 | MAP3K8 | AEH-subject4 | Human | Endometrium | AEH | 2.41e-21 | 6.70e-01 | -0.2657 |
1326 | MAP3K8 | AEH-subject5 | Human | Endometrium | AEH | 2.30e-13 | 5.32e-01 | -0.2953 |
1326 | MAP3K8 | EEC-subject1 | Human | Endometrium | EEC | 5.43e-10 | 4.72e-01 | -0.2682 |
1326 | MAP3K8 | EEC-subject2 | Human | Endometrium | EEC | 4.43e-18 | 5.36e-01 | -0.2607 |
1326 | MAP3K8 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 6.27e-03 | 4.41e-02 | -0.1869 |
1326 | MAP3K8 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 8.74e-03 | -2.49e-02 | -0.1875 |
1326 | MAP3K8 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.71e-02 | 1.12e-03 | -0.1883 |
1326 | MAP3K8 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.23e-03 | 6.17e-02 | -0.1917 |
1326 | MAP3K8 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 7.53e-06 | 7.26e-02 | -0.1916 |
1326 | MAP3K8 | LZE7T | Human | Esophagus | ESCC | 4.36e-09 | 5.37e-01 | 0.0667 |
1326 | MAP3K8 | LZE8T | Human | Esophagus | ESCC | 3.66e-09 | 1.81e-01 | 0.067 |
1326 | MAP3K8 | LZE20T | Human | Esophagus | ESCC | 1.48e-03 | 4.65e-01 | 0.0662 |
1326 | MAP3K8 | LZE24T | Human | Esophagus | ESCC | 2.94e-28 | 1.45e+00 | 0.0596 |
1326 | MAP3K8 | LZE21T | Human | Esophagus | ESCC | 1.94e-03 | 8.17e-01 | 0.0655 |
1326 | MAP3K8 | P1T-E | Human | Esophagus | ESCC | 2.21e-09 | 1.76e+00 | 0.0875 |
1326 | MAP3K8 | P2T-E | Human | Esophagus | ESCC | 8.72e-25 | 7.46e-01 | 0.1177 |
1326 | MAP3K8 | P4T-E | Human | Esophagus | ESCC | 1.12e-39 | 1.35e+00 | 0.1323 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005086316 | Oral cavity | EOLP | regulation of T cell activation | 76/2218 | 329/18723 | 5.96e-09 | 3.11e-07 | 76 |
GO:190303716 | Oral cavity | EOLP | regulation of leukocyte cell-cell adhesion | 77/2218 | 336/18723 | 6.89e-09 | 3.53e-07 | 77 |
GO:002240719 | Oral cavity | EOLP | regulation of cell-cell adhesion | 93/2218 | 448/18723 | 3.65e-08 | 1.41e-06 | 93 |
GO:00512517 | Oral cavity | EOLP | positive regulation of lymphocyte activation | 72/2218 | 362/18723 | 6.21e-06 | 1.22e-04 | 72 |
GO:190303915 | Oral cavity | EOLP | positive regulation of leukocyte cell-cell adhesion | 52/2218 | 239/18723 | 9.14e-06 | 1.70e-04 | 52 |
GO:00508677 | Oral cavity | EOLP | positive regulation of cell activation | 79/2218 | 420/18723 | 1.91e-05 | 3.02e-04 | 79 |
GO:00026968 | Oral cavity | EOLP | positive regulation of leukocyte activation | 77/2218 | 409/18723 | 2.34e-05 | 3.52e-04 | 77 |
GO:005087014 | Oral cavity | EOLP | positive regulation of T cell activation | 47/2218 | 216/18723 | 2.40e-05 | 3.58e-04 | 47 |
GO:002240918 | Oral cavity | EOLP | positive regulation of cell-cell adhesion | 57/2218 | 284/18723 | 4.23e-05 | 5.77e-04 | 57 |
GO:004578532 | Oral cavity | NEOLP | positive regulation of cell adhesion | 88/2005 | 437/18723 | 3.28e-09 | 1.95e-07 | 88 |
GO:002240724 | Oral cavity | NEOLP | regulation of cell-cell adhesion | 81/2005 | 448/18723 | 1.54e-06 | 3.83e-05 | 81 |
GO:000715923 | Oral cavity | NEOLP | leukocyte cell-cell adhesion | 70/2005 | 371/18723 | 1.65e-06 | 4.05e-05 | 70 |
GO:004211031 | Oral cavity | NEOLP | T cell activation | 86/2005 | 487/18723 | 2.01e-06 | 4.77e-05 | 86 |
GO:190303723 | Oral cavity | NEOLP | regulation of leukocyte cell-cell adhesion | 61/2005 | 336/18723 | 2.56e-05 | 4.01e-04 | 61 |
GO:005086323 | Oral cavity | NEOLP | regulation of T cell activation | 58/2005 | 329/18723 | 9.33e-05 | 1.15e-03 | 58 |
GO:002240923 | Oral cavity | NEOLP | positive regulation of cell-cell adhesion | 51/2005 | 284/18723 | 1.50e-04 | 1.72e-03 | 51 |
GO:190303923 | Oral cavity | NEOLP | positive regulation of leukocyte cell-cell adhesion | 42/2005 | 239/18723 | 8.66e-04 | 6.83e-03 | 42 |
GO:005087023 | Oral cavity | NEOLP | positive regulation of T cell activation | 38/2005 | 216/18723 | 1.45e-03 | 1.03e-02 | 38 |
GO:005125113 | Oral cavity | NEOLP | positive regulation of lymphocyte activation | 54/2005 | 362/18723 | 7.55e-03 | 3.77e-02 | 54 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0466814 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa046607 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0466013 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa046684 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa0466811 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa046689 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
hsa046606 | Oral cavity | OSCC | T cell receptor signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa04620 | Oral cavity | OSCC | Toll-like receptor signaling pathway | 58/3704 | 104/8465 | 8.77e-03 | 1.98e-02 | 1.01e-02 | 58 |
hsa0466816 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
hsa0466012 | Oral cavity | OSCC | T cell receptor signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa046201 | Oral cavity | OSCC | Toll-like receptor signaling pathway | 58/3704 | 104/8465 | 8.77e-03 | 1.98e-02 | 1.01e-02 | 58 |
hsa0466021 | Oral cavity | EOLP | T cell receptor signaling pathway | 34/1218 | 104/8465 | 1.63e-06 | 1.39e-05 | 8.18e-06 | 34 |
hsa0466841 | Oral cavity | EOLP | TNF signaling pathway | 35/1218 | 114/8465 | 5.79e-06 | 3.67e-05 | 2.16e-05 | 35 |
hsa0401023 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0466031 | Oral cavity | EOLP | T cell receptor signaling pathway | 34/1218 | 104/8465 | 1.63e-06 | 1.39e-05 | 8.18e-06 | 34 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K8 | SNV | Missense_Mutation | novel | c.497N>T | p.Cys166Phe | p.C166F | P41279 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MAP3K8 | SNV | Missense_Mutation | c.275N>G | p.Ser92Cys | p.S92C | P41279 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.819) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MAP3K8 | SNV | Missense_Mutation | c.905N>T | p.Arg302Met | p.R302M | P41279 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MAP3K8 | insertion | Frame_Shift_Ins | novel | c.429_430insGTATGTTTAGTAGAGATGGGTTTTC | p.Ile144ValfsTer32 | p.I144Vfs*32 | P41279 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
MAP3K8 | insertion | Nonsense_Mutation | novel | c.574_575insCAATTAATTACTCATGAGTAGGTGGAAATATGACCAGGTCTGACC | p.Glu192delinsAlaIleAsnTyrSerTerValGlyGlyAsnMetThrArgSerAspGln | p.E192delinsAINYS*VGGNMTRSDQ | P41279 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
MAP3K8 | insertion | In_Frame_Ins | novel | c.216_217insCGCAAGCGAGCGGGGCTTCTCCTCCCCAACCCCGGCCCAGGC | p.Trp72_Leu73insArgLysArgAlaGlyLeuLeuLeuProAsnProGlyProGly | p.W72_L73insRKRAGLLLPNPGPG | P41279 | protein_coding | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
MAP3K8 | SNV | Missense_Mutation | c.1063G>C | p.Asp355His | p.D355H | P41279 | protein_coding | deleterious(0) | benign(0.21) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
MAP3K8 | SNV | Missense_Mutation | novel | c.172N>A | p.Glu58Lys | p.E58K | P41279 | protein_coding | deleterious_low_confidence(0.01) | benign(0.14) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
MAP3K8 | SNV | Missense_Mutation | novel | c.71N>G | p.Ser24Cys | p.S24C | P41279 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.903) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAP3K8 | SNV | Missense_Mutation | c.751N>A | p.His251Asn | p.H251N | P41279 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1326 | MAP3K8 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 178102629 | ||
1326 | MAP3K8 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 178102673 |
Page: 1 |